on Evotec AG (NASDAQ:EVTCY)
Evotec and Bristol Myers Squibb Expand Protein Degradation Partnership
Evotec SE and Bristol Myers Squibb have announced the advancement of their strategic protein degradation collaboration with a second Investigational New Drug (IND) acceptance from the FDA. This clearance broadens their molecular glue pipeline. Launched in 2018, the partnership utilizes Evotec’s cutting-edge multi-omics screening and AI-assisted analytics alongside Bristol Myers Squibb’s CELMoD agent library to develop groundbreaking molecular glue degraders targeting difficult oncological proteins.
The second drug candidate, a cereblon E3 ligase modulator, is set to begin Phase 1 clinical trials in 2027. This development marks a continuation of their success in translating complex biology into therapeutic solutions aimed at addressing substantial unmet medical needs. The advanced platforms used in this partnership ensure the identification and development of promising drug candidates, reinforcing their role in innovative cancer treatment research.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Evotec AG news